Relation between cholinesterase inhibitor and Pisa syndrome.
We report two patients who developed Pisa syndrome after treatment with cholinesterase inhibitors--cognition-enhancing novel agents for patients with Alzheimer's disease. Cholinergic excess could be another factor in Pisa syndrome, especially in cholinergically-imbalanced Alzheimer's disease.
Kwak
Y T
YT
Han
I W
IW
Baik
J
J
Koo
M S
MS
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy; D002219:Carbamates / Q000009:adverse effects; D002800:Cholinesterase Inhibitors / Q000009:adverse effects*; D000077265:Donepezil; D018492:Dopamine Antagonists / Q000009:adverse effects; D004421:Dystonia / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007189:Indans / Q000009:adverse effects; D008569:Memory Disorders / Q000188:drug therapy; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000009:adverse effects; D018697:Nootropic Agents / Q000009:adverse effects; D048448:Phenylcarbamates; D010880:Piperidines / Q000009:adverse effects; D011187:Posture; D011595:Psychomotor Agitation / Q000188:drug therapy; D018967:Risperidone / Q000009:adverse effects; D000068836:Rivastigmine; D013577:Syndrome
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D018492:Dopamine Antagonists; D007189:Indans; D018696:Neuroprotective Agents; D018697:Nootropic Agents; D048448:Phenylcarbamates; D010880:Piperidines; D000077265:Donepezil; D018967:Risperidone; D000068836:Rivastigmine